{"id":"hip1402","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL836","moleculeType":"Small molecule","molecularWeight":"408.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HIP1402 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. Its extended half-life enables once-weekly or less frequent dosing.","oneSentence":"HIP1402 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:02.344Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04084197","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-12-19","conditions":"Healthy","enrollment":61},{"nctId":"NCT02390882","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-10","conditions":"Benign Prostate Hyperplasia","enrollment":494},{"nctId":"NCT02529800","phase":"PHASE1","title":"Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT02715401","phase":"PHASE1","title":"PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-10","conditions":"Erectile Dysfunction, Prostatic Hyperplasia","enrollment":36},{"nctId":"NCT02712411","phase":"PHASE1","title":"Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-07","conditions":"Erectile Dysfunction, Prostatic Hyperplasia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tamsulosin HCl 0.4mg"],"phase":"phase_3","status":"active","brandName":"HIP1402","genericName":"HIP1402","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HIP1402 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}